HONG KONG–(BUSINESS WIRE)–Jul 20, 2021–
CSOP Asset Administration Restricted (“CSOP”) is proud to announce the itemizing of CSOP China Healthcare Disruption Index ETF (inventory ticker: 3174.HK) on the Hong Kong Inventory Change (the “HKEX”). 3174.HK will monitor the efficiency of the Solactive China Healthcare Disruption Index (the “Index”). With itemizing value at round HKD 7.8 per unit, buying and selling lot of 100 shares and annual administration charge of 0.99%, CSOP China Healthcare Disruption Index ETF will begin to commerce on 21 July, 2021. Upon inception, 3174.HK has obtained round HKD 103 million preliminary funding.
This press launch options multimedia. View the total launch right here: https://www.businesswire.com/news/home/20210719005878/en/
(Graphic: Enterprise Wire)
The healthcare sector accommodates a various array of industries, together with biotechnology, Web-based medical providers, drug discovery and manufacturing providers and plenty of different associated providers. Since Covid-19 hit the world unexpectedly, the healthcare sector has obtained unprecedented consideration. In 2018, world spending on well being reached USD 8.3 trillion, or 10% of worldwide gross home product (GDP). 1 It’s anticipated to extend at an annual price of 4.9% from 2018 to 2022, attaining USD 10.05 trillion in 2022. 2 Presently, China has the second-largest healthcare trade on the planet. In comparison with a five-year compound annual development price (“CAGR”) of 4% in america, China’s healthcare market has grown quickly at a CAGR of 17%. 3 China’s healthcare market dimension is aimed to develop to about USD 2.4 trillion by 2030. 4 The onset of Covid-19 together with China’s ageing inhabitants has additional offered appreciable development alternatives for the healthcare sector, significantly in sub-sectors like telemedicine and biotech. Closely featured within the thirteenth 5-Yr Plan and the Wholesome China 2030 technique, Web-based healthcare in China has maintained a excessive CAGR of over 30%. 5 China’s authorities analysis & growth (“R&D”) spending on biotech topped USD 291 billion in 2019, whereas firms raised USD 16.5 billion throughout 90 fairness and debt choices, representing a 17% enhance in quantity and 13% enhance in worth from 2018. 6
In 2020, the healthcare sector within the Hong Kong inventory market confirmed sturdy development momentum and obtained vital market curiosity with 23 newly listed healthcare firms elevating a complete of HKD 98 billion. 7 To duplicate the sturdy efficiency of the fast-growing healthcare trade in Higher China, the Solactive China Healthcare Disruption Index comprehensively invests in as much as 35 most consultant Hong Kong-listed firms with enterprise operations in mainland China, Hong Kong, Taiwan and Macau. These firms concentrate on varied modern fields, starting from biotechnology and medical specialties to biopharmaceuticals, and healthcare gear to Web pharmacies and drug retail. Primarily based on historic back-testing information, the Index achieves a return of 36.6% over the prior 12 months. 8 Weighted by free-float market capitalization of constituents, the Index ensures the inclusion of essentially the most consultant firms in Higher China’s healthcare trade with a mixed scheme of quarterly rebalance and weekly IPO evaluation. As the tip of Could 2021, the entire market cap of the index is HKD 2.98 trillion. 9 Primarily adopting a bodily consultant sampling technique to duplicate the index, 3174.HK allows worldwide buyers to understand the funding alternatives of healthcare trade in a simple and clear approach.
The way forward for human beings embrace a wiser, greener and more healthy way of life. Because the pioneer ETF issuer in Hong Kong, CSOP has at all times been devoted to offering ETFs/ETPs that not solely serve the calls for of asset allocation, but in addition current the prospects of investments. 3174.HK is without doubt one of the necessary members of CSOP future-defining thematic ETFs.
Melody He, Managing Director, Head of Enterprise Growth and Product Technique & Options, says: “We’re delighted to deliver one other future-themed ETF to our buyers. The launch of 3174.HK allows buyers to understand the funding alternatives by pursuing a more healthy life extra simply and transparently. Among the many collection of CSOP future thematic ETFs, CSOP Grasp Seng TECH Index ETF (3033.HK), CSOP Yinhua CSI 5G Communications Theme ETF (3193.HK) 10 and CSOP International Cloud Computing Know-how Index ETF(3194.HK) are our solutions to growing demand for a extra clever way of life. CSOP Huatai-Pinebridge CSI Photovoltaic Business ETF (3134.HK) 11 additional completes a major piece of puzzle for a greener life. Extra CSOP’s future-themed ETFs will come to the market, unfolding the way forward for investments in entrance of buyers.”
About CSOP Asset Administration Restricted
CSOP Asset Administration Restricted (“CSOP”) was based in 2008 as the primary offshore asset supervisor arrange by a regulated asset administration firm in China. With a devoted concentrate on China investing, CSOP manages private and non-private funds, in addition to offering funding advisory providers to Asian and world buyers. As well as, CSOP is finest referred to as an ETF chief in Asia. As of 31 March 2021, CSOP has greater than USD 10 billion in belongings underneath administration.
This materials has not been reviewed by the Securities and Futures Fee.
Issuer: CSOP Asset Administration Restricted
Please confer with the providing paperwork for the index supplier disclaimer.
IMPORTANT: Funding includes dangers. Funding worth could rise or fall. Previous efficiency data offered isn’t indicative of future efficiency. Buyers ought to confer with the Prospectus and the Product Key Info Assertion for additional particulars, together with product options and danger components. Buyers shouldn’t base on this materials alone to make funding selections.
CSOP China Healthcare Disruption Index ETF:
- CSOP China Healthcare Disruption Index ETF (the “Sub-Fund”) isn’t principal assured and your investments could undergo losses. There is no such thing as a assurance that the Sub-Fund will obtain its funding goal.
- Solactive China Healthcare Disruption Index (the “Index”) is a brand new index. The Sub-Fund could also be riskier than different change traded funds monitoring extra established indices with longer working historical past
- The Index is topic to geographical focus dangers on account of monitoring the efficiency of primarily Hong Kong listed firms which have enterprise operations within the discipline of healthcare sector in mainland China, Hong Kong, Taiwan and Macau. The worth of the Sub-Fund could also be extra inclined to hostile financial, political, coverage, international change, liquidity, tax, authorized or regulatory occasion affecting the Hong Kong market and locations the place these firms have enterprise operations together with mainland China, Taiwan and Macau
- Dangers related to FDIs embrace counterparty/credit score danger, liquidity danger, valuation danger, volatility danger and over-the-counter transaction danger. FDIs are inclined to cost fluctuations and better volatility, and will have massive bid and supply spreads and no lively secondary markets. The leverage component/element of an FDI can lead to a loss considerably better than the quantity invested within the FDI by the Sub-Fund. Publicity to FDIs could result in a excessive danger of serious loss by the Sub-Fund
- The buying and selling value of the Shares on the SEHK is pushed by market components such because the demand and provide of the Shares. Due to this fact, the Shares could commerce at a considerable premium or low cost to the Sub-Fund’s NAV
Please notice that the above listed funding dangers aren’t exhaustive and buyers ought to learn the Prospectus and the Product Key Info Assertion intimately earlier than making any funding determination.
1 Supply: WHO, International Spending on Well being: Weathering the Storm, 2020 2 Supply: Deloitte, 2019 International Healthcare Outlook: Shaping the Future 3 Supply: WHO, 2018 4 Supply: China’s Nationwide Well being and Household Planning Fee (NHFPC) 5 Supply: Frost & Sullivan, 36Kr Analysis, 2012-2026 China’s Web Medical Market Scale and Forecast 6 Supply: Baker McKenzie, The Way forward for Capital Elevating in Biotech and Pharma 7 Supply: HKEX, February 2021 8 Supply: Solactive AG, 29 June 2021 9 Supply: Bloomberg 10 CSOP Yinhua CSI 5G Communications Theme ETF is a feeder fund. Its grasp fund, Yinhua CSI 5G Communication ETF, isn’t licensed by the Securities and Futures Fee for direct providing to the general public in Hong Kong.
11 CSOP Huatai-PineBridge CSI Photovoltaic Business ETF is a feeder fund. Its grasp fund, Huatai-PineBridge CSI Photovoltaic Business ETF, isn’t licensed by the Securities and Futures Fee for direct providing to the general public in Hong Kong.
View supply model on businesswire.com:https://www.businesswire.com/news/home/20210719005878/en/
CONTACT: CSOP Asset Administration Restricted
Larry Wang / 3406 5613 /[email protected]
Tina Shu/ 3406 5675/[email protected]
KEYWORD: HONG KONG CHINA SINGAPORE ASIA PACIFIC
INDUSTRY KEYWORD: SOFTWARE MANAGED CARE BANKING NETWORKS GENERAL HEALTH INTERNET PROFESSIONAL SERVICES PHARMACEUTICAL TECHNOLOGY BIOTECHNOLOGY FINANCE HEALTH
SOURCE: CSOP Asset Administration Restricted
Copyright Enterprise Wire 2021.
PUB: 07/20/2021 02:30 AM/DISC: 07/20/2021 02:31 AM